Laura-Ann Shaa Ling Chin, BSc, MSc, PE

Barry-Wehmiller Design Group
Director, Life Sciences
Laura-Ann Chin offers over 11 years of international and domestic contract and hands on process engineering experience in the design and construction of cGMP facilities in the US, Europe and Asia.

She specializes in Single-Use Solutions and Modular Technologies for Scale-Up, Scale-Out and Technology Transfer in maximizing the performance of ATMP, biotech, and bulk pharmaceutical facilities.

Laura-Ann’s dynamic proficiency in process engineering combines best business practices and technical expertise in executing projects with exceptional value, speed and compliance. She prides herself in engaging clients upfront and developing strong relationships in the design process.

In most recent years, Laura-Ann has taken a strong affinity in the development of Advanced Therapy Medicinal Products (ATMP) Clinical and Manufacturing facilities where she continues to extend value and creative solutions to cutting edge engineering clients. In addition, Laura-Ann has continued to provide leadership to the engineering design process through the development of highly customized PFDs & P&IDs, mass & energy balance, critical utility calculations, sensitivity analysis and process modeling, bioprocess and cGMP equipment design, hydraulic & pump calculations, vessel relief scenarios, HAZOP and Risk Assessment workshops and value engineering efforts.

Laura's present role as Director of Life Sciences with Barry-Wehmiller Design Group (BWDG) engages cross-linking years of authentic relationship building, coupled with dynamic leadership skills and sound technical knowledge to bring cutting-edge, bespoke and compelling solutions to the Life Sciences & Biotech community and beyond.

Related Articles

Industry 4.0 Machinery Production Facility
iSpeak Blog
Challenges and Trends in Biopharmaceutical Facility Design

Biopharmaceutical facility design is a critical aspect of the industry. Overall cost pressures in the global health system, regional requirements to deploy manufacturing rather than centralize manufacturing in one location, technology enhancements in cell biology and format, flexibility to accommodate multi-product campaigns with different production schedules, and speed-to-market are among...

When Speed to Market Counts
iSpeak Blog
When Speed to Market Counts

Speed to market is a major priority for life sciences companies and this is going to be a featured topic during the 2023 ISPE Biotechnology Conference. More than ever before, biotechnology companies are pushing for exponential growth by expediting the scalability of manufacturing processes and the use of different modalities. This can significantly accelerate patient access to life-saving...